title: Deep intrastromal bevacizumab injection for management of corneal stromal vascularization after deep anterior lamellar keratoplasty, a novel technique.
abstract: OBJECTIVE
  To report the effect of intrastromal injection of bevacizumab in an eye with extensive corneal stromal vascularization after deep anterior lamellar keratoplasty.
  
  
  METHODS
  Bevacizumab (2.5 mg/1 mL) was injected into the deep corneal stroma of an eye with severe and extensive stromal vascularization.
  
  
  RESULTS
  Corneal vascularization regressed dramatically after deep stromal injection of bevacizumab with no recurrence after 6 months. Visual acuity was improved, and the patient's complaints subsided.
  
  
  CONCLUSIONS
  Corneal intrastromal injection of bevacizumab can be considered for management of intrastromal vascularization after deep anterior lamellar keratoplasty.
authors.affiliation: Cornea Department, Eye Research Center, Farabi Eye Center, Tehran Medical University, Qazvin Square, Tehran, Iran. mahammadpour@yahoo.com
authors.forename: Mohammad Naser
authors.initials: MN
authors.lastname: Hashemian
authors.forename: Mohammad Ali
authors.initials: MA
authors.lastname: Zare
authors.forename: Firoozeh
authors.initials: F
authors.lastname: Rahimi
authors.forename: Mehrdad
authors.initials: M
authors.lastname: Mohammadpour
mesh_terms: D020533:Angiogenesis Inhibitors / Q000008:administration & dosage*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D016510:Corneal Neovascularization / Q000209:etiology* / Q000473:pathology; D003319:Corneal Stroma / Q000098:blood supply*; D016039:Corneal Transplantation / Q000009:adverse effects* / Q000379:methods*; D006801:Humans; D056965:Injections, Intraocular; D008297:Male; D016896:Treatment Outcome; D014792:Visual Acuity / Q000187:drug effects; D055815:Young Adult
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab